Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.42 - $0.72 $63,420 - $108,720
151,000 Added 61.16%
397,900 $250,000
Q3 2023

Nov 14, 2023

SELL
$0.6 - $1.53 $30,120 - $76,806
-50,200 Reduced 16.9%
246,900 $148,000
Q2 2023

Aug 14, 2023

BUY
$1.05 - $1.63 $21,525 - $33,415
20,500 Added 7.41%
297,100 $335,000
Q1 2023

May 15, 2023

SELL
$1.2 - $2.73 $228,240 - $519,246
-190,200 Reduced 40.75%
276,600 $373,000
Q4 2022

Feb 14, 2023

BUY
$1.71 - $3.61 $5,301 - $11,191
3,100 Added 0.67%
466,800 $868,000
Q3 2022

Nov 14, 2022

BUY
$1.9 - $8.63 $96,710 - $439,267
50,900 Added 12.33%
463,700 $1.14 Million

Others Institutions Holding NVTA

About Invitae Corp


  • Ticker NVTA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 235,266,000
  • Description
  • Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...
More about NVTA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.